about
Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial.Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in womenAge-Disparate Partnerships and Risk of HIV-1 Acquisition Among South African Women Participating in the VOICE Trial.Utility of colposcopy in a phase 2 portion of a microbicide clinical trial of BufferGel and 0.5% PRO 2000 Gel.Mucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial.An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African WomenUse of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in WomenContraceptive Use and Pregnancy Incidence Among Women Participating in an HIV Prevention Trial.Genotypic diversity of anogenital human papillomavirus in women attending cervical cancer screening in Harare, Zimbabwe.Corrigendum to "oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial" [contraception 2016; 93 (1): 25-31].Acceptability of heat treating breast milk to prevent mother-to-child transmission of human immunodeficiency virus in Zimbabwe: a qualitative study.Misreporting of contraceptive hormone use in clinical research participants.Impact of contraceptive initiation on vaginal microbiota.Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in WomenThe association of puerperal sepsis with HIV infection at two tertiary hospitals in ZimbabweAnal human papillomavirus infection in HIV-positive men and women at two opportunistic infections clinics in Harare, Zimbabwe
P50
Q31014284-77A7774D-2502-41E6-927F-D22F028AA1EEQ34874237-23DB4CC3-978F-4B1A-82EA-F98CFC7E31E1Q36068808-50AEFF9A-6684-48FD-8CEF-D3AF60F8D048Q36386833-064232A8-37C6-43DA-A204-377527E17C7AQ36412234-C85246FE-790B-45DB-BED1-68EC3BC2B4EDQ37014243-7208084D-98E8-4195-BB61-9136715FFE57Q37194802-6522492C-6F00-44C7-8018-A14B5FBBBDD2Q38823078-9EE4F416-0A3B-4795-8FE8-902C23F3F979Q38846847-29018C98-AD31-4BFB-A68C-AD747C0E5C0DQ44696519-B2C8670B-CEB1-4921-85DC-CE3DD6EDC1CFQ45419974-CFB100EE-DF8E-471E-9838-808BC4E90391Q46010525-1B06DD00-1385-4247-87CD-407FC63AC2A0Q53700728-4B871958-2962-4FC1-91E3-BE60D2C7A7ECQ57207482-9EDC6CA3-308B-47FE-962F-EDCE860B3F4FQ57806570-4545D852-F659-40EC-9C4B-98F8E03F59E7Q59340491-2FCF3838-BAE3-4AEC-ADE0-3B886FE6E589
P50
name
Zvavahera M Chirenje
@en
type
label
Zvavahera M Chirenje
@en
prefLabel
Zvavahera M Chirenje
@en